Gout/Hyperuricemia
Conditions
Interventions
Allopurinol Group:Allopurinol is recommended to start at 100mg and 50mg for patients with renal insufficiency
Febuxostat Group:Febuxostat start at 20mg
Benzbromarone Group:Benzbromarone start at 25mg
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 75 years old, male or female; 2. Patients with hyperuricemia and a history of gout attack and blood uric acid level > 8.0mg/dl (480umol/l); 3. Volunteer and sign informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with severe renal function impairment (eGFR < 30ml/min*1.73m2) (2009EP formula); 2. Patients with ALT or AST more than 2 times of the upper limit of normal (patients with abnormal liver function, but whose ALT or AST not exceed 3 times of the upper limit of normal, and can be explained by fatty liver can include into the study); 3. Women who are breast-feeding or pregnant, and those who plan to get pregnant, not willing to or havent take sufficient contraceptive measures during the period of childbearing age; 4. Have a history of allergy to any ingredient of uric acid lowering drugs; 5. Patients receiving azathiopurine or mercaptopurine therapy; 6. Inability or unwillingness to offer informed consent or to comply with the trial requirements; 7. Other factors researchers consider not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major Adverse Cardiovascular Events;Chinese cardiovascular and cerebrovascular assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute gout attack;eGFR;Liver fuction;Blood pressure;Blood routine; | — |
Countries
China
Contacts
Public ContactZou Hejian
Huashan Hospital, Fudan University
Outcome results
None listed